Teladoc Health (TDOC) 10-Q 26 Apr 24 2024 Q1 Quarterly report Financial data

COVER PAGE

COVER PAGE - shares	3 Months Ended
	Mar. 31, 2024	Apr. 22, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-37477
Entity Registrant Name	TELADOC HEALTH, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3705970
Entity Address, Address Line One	2 Manhattanville Road
Entity Address, Address Line Two	Suite 203
Entity Address, City or Town	Purchase
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10577
City Area Code	203
Local Phone Number	635-2002
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	TDOC
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		169,588,171
Entity Central Index Key	0001477449
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,097,935	$ 1,123,675
Accounts receivable, net of allowance for doubtful accounts of $3,530 and $4,240 at March 31, 2024 and December 31, 2023, respectively	214,293	217,423
Inventories	32,268	29,513
Prepaid expenses and other current assets	141,769	118,437
Total current assets	1,486,265	1,489,048
Property and equipment, net	29,550	32,032
Goodwill	1,073,190	1,073,190
Intangible assets, net	1,614,238	1,677,781
Operating lease - right-of-use assets	37,506	40,060
Other assets	80,007	80,258
Total assets	4,320,756	4,392,369
Current liabilities:
Accounts payable	37,674	43,637
Accrued expenses and other current liabilities	199,418	178,634
Accrued compensation	50,523	102,686
Deferred revenue-current	101,229	95,659
Total current liabilities	388,844	420,616
Other liabilities	1,023	1,080
Operating lease liabilities, net of current portion	39,971	42,837
Deferred revenue, net of current portion	15,002	13,623
Deferred taxes, net	47,472	49,452
Convertible senior notes, net	1,539,546	1,538,688
Commitments and contingencies (Note 14)
Stockholders’ equity:
Common stock, $0.001 par value; 300,000,000 shares authorized; 169,314,029 shares and 166,658,253 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	169	167
Additional paid-in capital	17,637,902	17,591,551
Accumulated deficit	(15,310,544)	(15,228,655)
Accumulated other comprehensive loss	(38,629)	(36,990)
Total stockholders’ equity	2,288,898	2,326,073
Total liabilities and stockholders’ equity	$ 4,320,756	$ 4,392,369

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Allowance for accounts receivable	$ 3,530	$ 4,240
Common stock par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	300,000,000	300,000,000
Common stock, issued (in shares)	169,314,029	166,658,253
Common stock, outstanding (in shares)	169,314,029	166,658,253

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 646,131	$ 629,244
Expenses:
Cost of revenue (exclusive of depreciation and amortization, which are shown separately below)	194,538	190,107
Operating expenses:
Advertising and marketing	183,329	176,790
Sales	54,364	54,490
Technology and development	81,388	86,985
General and administrative	111,697	114,145
Acquisition, integration, and transformation costs	373	5,944
Restructuring costs	9,673	8,102
Amortization of intangible assets	95,057	66,860
Depreciation of property and equipment	2,834	2,923
Total expenses	733,253	706,346
Loss from operations	(87,122)	(77,102)
Interest income	(13,942)	(8,911)
Interest expense	5,649	5,263
Other expense (income), net	370	(4,907)
Loss before provision for income taxes	(79,199)	(68,547)
Provision for income taxes	2,690	681
Net loss	(81,889)	(69,228)
Other comprehensive loss, net of tax:
Currency translation adjustment	(1,639)	1,779
Comprehensive loss	$ (83,528)	$ (67,449)
Net loss per share, basic (in dollars per share)	$ (0.49)	$ (0.42)
Net loss per share, diluted (in dollars per share)	$ (0.49)	$ (0.42)
Weighted-average shares used to compute basic net loss per share (in shares)	167,730,746	162,922,691
Weighted-average shares used to compute diluted net loss per share (in shares)	167,730,746	162,922,691

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Gain (Loss)
Balance as of beginning of the period (in shares) at Dec. 31, 2022		162,840,360
Balance as of beginning of the period at Dec. 31, 2022	$ 2,307,745	$ 163	$ 17,358,645	$ (15,008,287)	$ (42,776)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		28,127
Exercise of stock options	296		296
Issuance of common stock upon vesting of restricted stock units (in shares)		1,050,907
Issuance of common stock upon vesting of restricted stock units	0	$ 1	(1)
Stock-based compensation	50,634		50,634
Other comprehensive income (loss), net of tax	1,779				1,779
Net loss	(69,228)			(69,228)
Balance as of end of the period (in shares) at Mar. 31, 2023		163,919,394
Balance as of end of the period at Mar. 31, 2023	2,291,226	$ 164	17,409,574	(15,077,515)	(40,997)
Balance as of beginning of the period (in shares) at Dec. 31, 2023		166,658,253
Balance as of beginning of the period at Dec. 31, 2023	$ 2,326,073	$ 167	17,591,551	(15,228,655)	(36,990)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	24,072	24,072
Exercise of stock options	$ 131		131
Issuance of common stock upon vesting of restricted stock units (in shares)		2,631,704
Issuance of common stock upon vesting of restricted stock units	0	$ 2	(2)
Stock-based compensation	46,222		46,222
Other comprehensive income (loss), net of tax	(1,639)				(1,639)
Net loss	(81,889)			(81,889)
Balance as of end of the period (in shares) at Mar. 31, 2024		169,314,029
Balance as of end of the period at Mar. 31, 2024	$ 2,288,898	$ 169	$ 17,637,902	$ (15,310,544)	$ (38,629)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (81,889)	$ (69,228)
Adjustments to reconcile net loss to net cash flows from operating activities:
Amortization of intangible assets	95,057	66,860
Depreciation of property and equipment	2,834	2,923
Amortization of right-of-use assets	2,614	3,056
Provision for allowances for doubtful accounts	86	3,794
Stock-based compensation	42,325	46,038
Deferred income taxes	(1,600)	(355)
Other, net	1,403	3,244
Changes in operating assets and liabilities:
Accounts receivable	2,133	(14,046)
Prepaid expenses and other current assets	(23,691)	(6,165)
Inventory	(3,091)	10,000
Other assets	1,009	(9,939)
Accounts payable	(5,870)	(9,132)
Accrued expenses and other current liabilities	25,185	15,452
Accrued compensation	(51,973)	(32,265)
Deferred revenue	7,297	5,648
Operating lease liabilities	(2,861)	(2,858)
Other liabilities	(48)	129
Net cash provided by operating activities	8,920	13,156
Cash flows from investing activities:
Capital expenditures	(1,149)	(2,363)
Capitalized software development costs	(34,363)	(43,261)
Net cash used in investing activities	(35,512)	(45,624)
Cash flows from financing activities:
Net proceeds from the exercise of stock options	131	296
Proceeds from employee stock purchase plan	1,516	2,731
Cash received for withholding taxes on stock-based compensation, net	106	496
Other, net	(2)	(170)
Net cash provided by financing activities	1,751	3,353
Net decrease in cash and cash equivalents	(24,841)	(29,115)
Effect of foreign currency exchange rate changes	(899)	(488)
Cash and cash equivalents at beginning of the period	1,123,675	918,182
Cash and cash equivalents at end of the period	1,097,935	888,579
Income taxes (refunded) paid, net	(245)	346
Interest paid	0	194
Supplemental disclosure of non-cash investing activities
Accruals related to Property and equipment, net and Intangible assets, net	$ 3,673	$ 5,516

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health,” or the “Company,” and is the global leader in whole person virtual care, forging a new healthcare experience with better convenience, outcomes, and value. The Company’s mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience . The Company was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. The Company’s principal executive office is located in Purchase, New York.

Basis of Presentation and Princ

Basis of Presentation and Principles of Consolidation	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements for t he three months ended March 31, 2024 and 2023, in the opinion of management, reflect all adjustments (consisting of normal recurring ac cruals) necessary for a fair presentation of the Condensed Consolidated Results of Operations, financial position and cash flows of Teladoc Health for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States (“U.S.”) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended December 31, 2023 (the “2023 Form 10-K”), which includes a complete set of footnote disclosures, including the Company’s significant accounting policies. These consolidated financial statements include the results of Teladoc Health, as well as two professional associations and 10 professional corporations (collectively, the “THMG Association”). Teladoc Health Medical Group, P.A., formerly Teladoc Physicians, P.A. (“THMG”), is party to a Services Agreement by and among it and the professional associations and professional corporations pursuant to which each professional association and professional corporation provides services to THMG. Each professional association and professional corporation is established pursuant to the requirements of its respective domestic jurisdiction governing the corporate practice of medicine. The Company holds a variable interest in the THMG Association, which contracts with physicians and other health professionals in order to provide services to Teladoc Health. The THMG Association is considered a variable interest entity (“VIE”) since it does not have sufficient equity to finance its activities without additional subordinated financial support. An enterprise having a controlling financial interest in a VIE must consolidate the VIE if it has both power and benefits—that is, it has (1) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). The Company has the power and rights to control all activities of the THMG Association and funds and absorbs all losses of the VIE and appropriately consolidates the THMG Association. Total revenue and net loss for the VIE were $70.0 million and $0.0 million and $61.6 million and $0.0 million for the three months ended March 31, 2024 and 2023, respectively. The VIE’s total assets, all of which were current, were $21.4 million and $20.6 million at March 31, 2024 and December 31, 2023, respectively. The VIE’s total liabilities, all of which were current, were $70.0 million and $69.2 million at March 31, 2024 and December 31, 2023, respectively. The VIE’s total stockholders’ deficit was $48.6 million and $48.6 million at March 31, 2024 and December 31, 2023, respectively. All intercompany transactions and balances have been eliminated. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business and economic factors, and various other assumptions that the Company believes are necessary to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s condensed consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves. The Company believes that estimates used in the preparation of these condensed consolidated financial statements are reasonable; however, actual results could differ materially from these estimates. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in the Condensed Consolidated Statements of Operations; if material, the effects of changes in estimates are disclosed in the Notes to Unaudited Condensed Consolidated Financial Statements. Significant estimates and assumptions by management affect areas including the value and useful life of long-lived assets (including intangible assets), the capitalization and amortization of software development costs, deferred device and contract costs, allowances for sales and for doubtful accounts, and the accounting for business combinations. Other significant areas include revenue recognition (including performance guarantees), the accounting for income taxes, contingencies, litigation and related legal accruals, the accounting for stock-based compensation awards, and other items as described in Note 2. “Basis of Presentation and Principles of Consolidation" in the Summary of Significant Accounting policies in the 2023 Form 10-K and as may be updated in this Quarterly Report in Note 2. “Basis of Presentation and Principles of Consolidation." Fair Value Measurements The carrying value of the Company’s cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximates fair value due to their short-term nature. A financial instrument’s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value: Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2—Include other inputs that are directly or indirectly observable in the marketplace. Level 3—Unobservable inputs that are supported by little or no market activity. The Company measures its cash equivalents at fair value on a recurring basis. The Company classifies its cash equivalents within Level 1 because they are valued using observable inputs that reflect quoted prices for identical assets in active markets and quoted prices directly in active markets. Reclassifications Certain prior year amounts have been reclassified to conform to the current year presentation. Recently Issued Accounting Standards In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, “Segment Reporting (Topic 280)—Improvements to Report Segment Disclosures” which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses so that investors can better understand an entity’s overall performance. The amendments are effective for annual reporting periods beginning after December 15, 2023, and interim periods, beginning after December 15, 2024, with early adoption permitted. The provisions of ASU 2023-07 are to be applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company is currently evaluating the impact of adopting ASU 2023-07 on its financial disclosures. In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvement to Income Tax Disclosures" to enhance the transparency and decision usefulness of income tax disclosures through expansion of disclosures in an entity’s income tax rate reconciliation table and regarding cash taxes paid both in the U.S. and foreign jurisdictions. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 on a prospective basis with early adoption permitted. The Company is currently evaluating the impact of ASU 2023-09 on its financial disclosures. In March 2024, the SEC issued Release Nos. 33-11275; 34-99678 "The Enhancement and Standardization of Climate-Related Disclosures for Investors" to improve the consistency, comparability, and reliability of disclosures on the financial effects of climate-related risks on a registrant's operations and how it manages these risks. The compliance date for this release was scheduled to be fiscal year 2025 for large accelerated filers. On April 4, 2024, the SEC voluntarily stayed implementation of this new rule pending judicial review. The Company is currently analyzing the impact that the new climate-related rules will have on its consolidated financial statements.

Revenue, Deferred Revenue, and

Revenue, Deferred Revenue, and Deferred Device and Contract Costs	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenue, Deferred Revenue, and Deferred Device and Contract Costs	Revenue, Deferred Revenue, and Deferred Device and Contract Costs The Company generates access fees from customers, which primarily consist of employers, health plans, hospitals and health systems, insurance and financial services companies (collectively “Clients”), as well as individual paying users, accessing its professional provider network, hosted virtual healthcare platform, and chronic care management platforms. Visit fee revenue is generated for general medical, expert medical service, and other specialty visits and is reported as a component of other revenue in the financial statements. Revenue associated with virtual healthcare device equipment sales included with the Company’s hosted virtual healthcare platform is also reported in other revenue. The following table presents the Company’s revenues disaggregated by revenue source and also by geography (in thousands): Three Months Ended 2024 2023 Revenue by Type Access fees $ 557,174 $ 550,870 Other 88,957 78,374 Total Revenue $ 646,131 $ 629,244 Revenue by Geography U.S. Revenue $ 547,600 $ 541,662 International Revenue 98,531 87,582 Total Revenue $ 646,131 $ 629,244 Deferred Revenue Deferred revenue represents billed, but unrecognized revenue, and is comprised of fees received in advance of the delivery or completion of the services and amounts received in instances when revenue recognition criteria have not been met. The Company records deferred revenue when cash payments are received in advance of the Company’s performance obligation to provide services. Deferred revenue is derived from 1) upfront payments for a device, which is amortized ratably over the expected member enrollment period; 2) upfront payments for certain services where payment is required for future periods before the service is delivered to the member, which is recognized when the services are provided; and 3) upfront payments from third-party financing companies with whom the Company works to provide certain Clients with a rental option, which is recognized over the rental period. Deferred revenue that will be recognized during the next twelve-month period is recorded as current deferred revenue and the remaining portion is recorded as non-current deferred revenue. The following table summarizes deferred revenue activities for the periods presented (in thousands): Three Months Ended 2024 2023 Beginning balance $ 109,283 $ 113,786 Cash collected 63,061 67,242 Revenue recognized (56,113) (61,697) Ending balance $ 116,231 $ 119,331 The Company expects to recognize $94.0 million of revenue throughout the remainder of 2024, $17.3 million of revenue in the year ending December 31, 2025, and the remaining balance thereafter related to future performance obligations that are unsatisfied or partially unsatisfied as of March 31, 2024. Deferred Device and Contract Costs Deferred device and contract costs are classified as a component of prepaid expenses and other current assets or other assets, depending on term, and consisted of the following (in thousands): As of March 31, As of December 31, Deferred device and contract costs, current $ 34,199 $ 32,703 Deferred device and contract costs, noncurrent 17,344 17,573 Total deferred device and contract costs $ 51,543 $ 50,276 Deferred device and contract costs were as follows (in thousands): Deferred Device and Contract Costs Beginning balance as of December 31, 2023 $ 50,276 Additions 12,239 Cost of revenue recognized (10,972) Ending balance as of March 31, 2024 $ 51,543

Inventories

Inventories	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consisted of the following (in thousands): As of March 31, As of December 31, Raw materials and purchased parts $ 11,529 $ 9,338 Work in process 678 299 Finished goods 20,061 19,876 Total inventories $ 32,268 $ 29,513

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): As of March 31, As of December 31, Prepaid expenses $ 85,477 $ 65,651 Deferred device and contract costs, current 34,199 32,703 Other receivables 13,559 12,640 Other current assets 8,534 7,443 Total prepaid expenses and other current assets $ 141,769 $ 118,437

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill Goodwill consisted of the following (in thousands): Teladoc Health Integrated BetterHelp Total Balance as of December 31, 2023 and March 31, 2024 $ — $ 1,073,190 $ 1,073,190 The Company performed a qualitative assessment of goodwill for its BetterHelp reporting unit as of October 1, 2023. As part of the Company's qualitative analysis, it considered the performance of the reporting unit compared to expectations, forecasts for revenue and margin, macroeconomic conditions, industry and market trends, as well as other relevant entity-specific items. Based on this qualitative assessment, no indicators of impairment were identified. While it is believed that the assumptions used were reasonable, changes in these assumptions for the BetterHelp reporting unit, including lowering forecasts for revenue and margin, lowering the long-term growth rate, or changes in the future discount rate assumptions, could result in a future impairment. In addition, if the Company experiences sustained significant decreases in its share price, this may also result in the need to perform impairment assessments of goodwill and long-lived assets including definite-lived intangibles that could also result in future impairments.

Intangible Assets, Net and Cert

Intangible Assets, Net and Certain Cloud Computing Costs	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net and Certain Cloud Computing Costs	Intangible Assets, Net and Certain Cloud Computing Costs Intangible assets, net consisted of the following (in thousands, except years): Useful Gross Value Accumulated Net Carrying Weighted March 31, 2024 Client relationships 2 to 20 years $ 1,458,261 $ (415,879) $ 1,042,382 12.3 Trademarks 2 to 15 years 325,022 (214,080) 110,942 6.6 Software 3 to 5 years 489,041 (191,956) 297,085 2.4 Acquired technology 4 to 7 years 341,741 (177,912) 163,829 3.5 Intangible assets, net $ 2,614,065 $ (999,827) $ 1,614,238 9.2 December 31, 2023 Client relationships 2 to 20 years $ 1,460,857 $ (391,196) $ 1,069,661 12.5 Trademarks 2 to 15 years 325,479 (189,330) 136,149 6.9 Software 3 to 5 years 456,583 (161,108) 295,475 2.5 Acquired technology 4 to 7 years 341,814 (165,318) 176,496 3.7 Intangible assets, net $ 2,584,733 $ (906,952) $ 1,677,781 9.3 The following table presents the Company's amortization of intangible assets expense by component (in thousands): Three Months Ended 2024 2023 Amortization of acquired intangibles $ 64,181 $ 50,259 Amortization of capitalized software development costs 30,876 16,601 Amortization of intangible assets expense $ 95,057 $ 66,860 During the second half of 2023 , the Company initiated a strategy to transition the majority of its chronic condition management Clients and members to the Teladoc Health brand on a phased basis, with a smaller subset continuing to be served under the Livongo trade name beyond 2024. In connection with the brand strategy, the Company has accelerated the amortization of intangible assets that are associated with the Livongo trademark, increasing amortization of intangible assets expense beginning in the second half of the year ending December 31, 2023 and continuing thereafter. The change in accounting estimate resulted in additional amortization of intangible assets expense of $18.6 million, or $0.11 per basic and diluted share for the three months ended March 31, 2024 . Periodic amortization of intangible assets that will be charged to expense over the remaining life of the intangible assets as of March 31, 2024 was as follows (in thousands): Years Ending December 31, 2024 $ 272,784 2025 280,727 2026 223,039 2027 163,836 2028 and thereafter 673,852 $ 1,614,238

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities As of March 31, As of December 31, Client performance guarantees and accrued rebates $ 36,282 $ 36,934 Marketing and advertising 38,724 34,427 Consulting fees/provider fees 16,443 16,416 Franchise, sales and other taxes 12,931 12,933 Operating lease liabilities – current 10,744 10,752 Professional fees 10,137 9,910 Information technology 7,968 7,605 Insurance 6,530 5,777 Interest payable 5,812 1,481 Income tax payable 4,127 621 Staff augmentation 3,532 4,287 Lease abandonment obligation - current 3,489 3,800 Other 42,699 33,691 Total $ 199,418 $ 178,634

Convertible Senior Notes

Convertible Senior Notes	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Convertible Senior Notes	Convertible Senior Notes Outstanding Convertible Senior Notes As of March 31, 2024, the Company had three series of convertible senior notes outstanding. The issuances of such notes originally consisted of (i) $1.0 billion aggregate principal amount of 1.25% convertible senior notes due 2027 (the “2027 Notes”), issued on May 19, 2020 for net proceeds to the Company of $975.9 million after deducting offering costs of approximately $24.1 million, (ii) $287.5 million aggregate principal amount of 1.375% convertible senior notes due 2025 (the “2025 Notes”), issued on May 8, 2018 for net proceeds to the Company of $279.1 million after deducting offering costs of approximately $8.4 million, and (iii) $550.0 million aggregate principal amount of 0.875% convertible senior notes due 2025 that were issued by Livongo Health, Inc. (“Livongo”) on June 4, 2020 for which the Company agreed to assume all of Livongo’s rights and obligations (the “Livongo Notes;” and together with the 2027 Notes and the 2025 Notes, the “Notes”). The following table presents certain terms of the Notes that were outstanding as of March 31, 2024: 2027 Notes 2025 Notes Livongo Notes Principal Amount Outstanding as of March 31, 2024 (in millions) $ 1,000.0 $ 0.7 $ 550.0 Interest Rate Per Year 1.25 % 1.375 % 0.875 % Fair Value as of March 31, 2024 (in millions) (1) $ 843.0 $ 0.2 $ 519.8 Fair Value as of December 31, 2023 (in millions) (1) $ 822.0 $ 0.3 $ 513.7 Maturity Date June 1, 2027 May 15, 2025 June 1, 2025 Optional Redemption Date June 5, 2024 May 22, 2022 June 5, 2023 Conversion Date December 1, 2026 November 15, 2024 March 1, 2025 Conversion Rate Per $1,000 Principal Amount as of March 31, 2024 4.1258 18.6621 13.9400 Remaining Contractual Life as of March 31, 2024 3.2 years 1.1 years 1.2 years (1) The Company estimates the fair value of its Notes utilizing market quotations for debt that have quoted prices in active markets. Since the Notes do not trade on a daily basis in an active market, the fair value estimates are based on market observable inputs based on borrowing rates currently available for debt with similar terms and average maturities. The Notes would be classified as Level 2 within the fair value hierarchy, as defined in Note 2. “Basis of Presentation and Principles of Consolidation.” All of the Notes are unsecured obligations of the Company and rank senior in right of payment to the Company’s indebtedness that is expressly subordinated in right of payment to such Notes; equal in right of payment to the Company’s liabilities that are not so subordinated; effectively junior in right of payment to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities incurred by the Company’s subsidiaries. Holders may convert all or any portion of their Notes in integral multiples of $1,000 principal amount, at their option, at any time prior to the close of business on the business day immediately preceding the applicable conversion date only under the following circumstances: • during any quarter (and only during such quarter), if the last reported sale price of the shares of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding quarter is greater than or equal to 130% of the conversion price for the applicable Notes on each applicable trading day; • during the five business day period after any 10 consecutive trading day period (or five consecutive trading day period in the case of the Livongo Notes) in which the trading price was less than 98% of the product of the last reported sale price of Company’s common stock and the conversion rate for the applicable Notes on each such trading day; • upon the occurrence of specified corporate events described under the applicable indenture; or • if the Company calls the applicable Notes for redemption, at any time until the close of business on the second business day immediately preceding the redemption date. On or after the applicable conversion date, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of such Notes, regardless of the foregoing circumstances. The 2027 Notes and the 2025 Notes are convertible into shares of the Company’s common stock at the applicable conversion rate shown in the table above. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination thereof, at the Company’s election. If the Company elects to satisfy the conversion obligation solely in cash or through payment and delivery, as the case may be, of a combination of cash and shares of the Company’s common stock, the amount of cash and shares of the Company’s common stock due upon conversion will be based on a daily conversion value calculated on a proportionate basis for each trading day in a 25 consecutive trading day observation period. The Livongo Notes are convertible at the applicable conversion rate shown in the table above into “units of reference property,” each of which is comprised of 0.592 of a share of the Company’s common stock and $4.24 in cash, without interest. Upon conversion, the Company will pay or deliver, as the case may be, cash, units of reference property, or a combination thereof, at the Company’s election. If the Company elects to satisfy the conversion obligation solely in cash or through payment and delivery, as the case may be, of a combination of cash and units of reference property, the amount of cash and units of reference property, if any, due upon conversion will be based on a daily conversion value calculated on a proportionate basis for each trading day in a 40 consecutive trading day observation period. For each Note series, the Company may redeem for cash all or part of the Notes, at its option, on or after the applicable optional redemption date shown in the table above (and prior to the 41 st scheduled trading day immediately preceding the maturity date in the case of the Livongo Notes) if the last reported sale price of its common stock exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including, the trading day immediately preceding the date on which the Company provides notice of the redemption. The redemption price will be the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any. In addition, calling any 2027 Note or 2025 Note for redemption on or after the applicable optional redemption date will constitute a make-whole fundamental change with respect to that Note, in which case the conversion rate applicable to the conversion of that Note, if it is converted in connection with the redemption, will be increased in certain circumstances as described in the applicable indenture. If the Company undergoes a fundamental change (as defined in the applicable indenture) at any time prior to the maturity date of the Livongo Notes, holders will have the right, at their option, to require the Company to repurchase for cash all or any portion of their Livongo Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Livongo Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company accounts for each Note series at amortized cost within the liability section of its Condensed Consolidated Balance Sheets. The Company has reserved an aggregate of 8.7 million shares of common stock for the Notes. The net carrying values of the Notes consisted of the following (in thousands): As of March 31, As of December 31, 2027 Notes Principal $ 1,000,000 $ 1,000,000 Less: Debt discount, net (1) (11,175) (12,033) Net carrying amount 988,825 987,967 2025 Notes Principal 725 725 Less: Debt discount, net (1) (4) (4) Net carrying amount 721 721 Livongo Notes Principal 550,000 550,000 Less: Debt discount, net (1) — — Net carrying amount 550,000 550,000 Total net carrying amount $ 1,539,546 $ 1,538,688 (1) Included in the accompanying Condensed Consolidated Balance Sheets within convertible senior notes and amortized to interest expense over the expected life of the Notes using the effective interest rate method. The following table sets forth total interest expense recognized related to the Notes (in thousands): Three Months Ended 2027 Notes 2024 2023 Contractual interest expense $ 3,125 $ 3,125 Amortization of debt discount 858 844 Total $ 3,983 $ 3,969 Effective interest rate 1.6 % 1.6 % Three Months Ended 2025 Notes 2024 2023 Contractual interest expense $ 2 $ 2 Amortization of debt discount 1 1 Total $ 3 $ 3 Effective interest rate 1.8 % 1.6 % Three Months Ended Livongo Notes 2024 2023 Contractual interest expense $ 1,203 $ 1,203 Amortization of debt discount — — Total $ 1,203 $ 1,203 Effective interest rate 0.9 % 1.3 %

Leases

Leases	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Leases	Leases Operating Leases The Company has operating leases for facilities, hosting co-location facilities, and certain equipment under non-cancelable leases in the U.S. and various international locations. The leases have remaining lease terms of less than one one The Company leases office space under non-cancelable operating leases in the U.S. and various international locations. The future minimum lease payments under non-cancelable operating leases were as follows (in thousands): Operating Leases: As of March 31, 2024 $ 9,979 2025 12,260 2026 11,101 2027 8,088 2028 5,918 2029 and thereafter 12,985 Total future minimum payments 60,331 Less: imputed interest (9,616) Present value of lease liabilities $ 50,715 Accrued expenses and other current liabilities $ 10,744 Operating lease liabilities, net of current portion $ 39,971 The Company rents certain virtual healthcare platforms to selected qualified customers under arrangements that qualify as either sales-type lease or operating lease arrangements. Leases have terms that generally range from two The Company recorded certain restructuring costs related to lease impairments and the related charges due to the abandonment and/or exit of excess leased office space. However, the lease liabilities related to these spaces remain an outstanding obligation of the Company as of March 31, 2024. See Note. 11, “Restructuring,” for further information.

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2024
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring The Company accounts for restructuring costs in accordance with ASC Subtopic 420-10, "Exit or Disposal Cost Obligations" and ASC Section 360-10-35, "Property, Plant and Equipment-Subsequent Measurement." The costs are recorded to the "Restructuring costs" line item within the Company's Condensed Consolidated Statements of Operations and Other Comprehensive Loss as they are recognized. The Company previously disclosed that, as a result of its comprehensive operational review of the business and in order to drive efficiency to reduce costs and improve profit growth, it expected to incur pre-tax charges in the range of $12 million to $16 million in the year ending December 31, 2024. The charges will primarily relate to employee transition, severance, employee benefits, and related costs needed to execute on various optimization initiatives. During the three months ended March 31, 2024, the Company recorded $9.7 million of restructuring costs, of which $7.0 million was for employee transition, severance, employee benefits, and related costs and $2.7 million was for other restructuring related costs. The portion of these expenses that are to be settled by cash disbursements were accounted for as a restructuring liability under the line item "Accrued expenses and other current liabilities" in the Company's Condensed Consolidated Balance Sheets. During the three months ended March 31, 2023, the Company recorded $8.1 million of restructuring costs, of which $7.2 million was related to employee transition, severance, employee benefits, and related costs and $0.9 million was related to costs associated with office space reductions. The table below summarizes the accrual and charges incurred and cash payments made with respect to the Company's restructurings, with the severance related portion included in the line item "Accrued compensation" and the lease termination and other related portion included in the line item "Accrued expenses and other current liabilities" in the Company's Condensed Consolidated Balance Sheet as of March 31, 2024 (in thousands): Restructuring Plan Severance Lease Termination Other (1) Total Accrued Balance, December 31, 2023 $ — $ 3,800 $ — $ 3,800 Additional expenses (recoveries) 6,957 (14) 2,730 9,673 Cash payments (6,769) (297) (953) (8,019) Accrued Balance, March 31, 2024 $ 188 $ 3,489 $ 1,777 $ 5,454

Common Stock and Stockholders'

Common Stock and Stockholders' Equity	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Common Stock and Stockholders' Equity	Common Stock and Stockholders’ Equity Stock Plans The Company’s 2023 Incentive Award Plan and 2023 Employment Inducement Incentive Award Plan (collectively, the “2023 Plans”) provide for the issuance of incentive and non-statutory options and other equity-based awards to its employees and non-employee service providers. Previously, the Company’s 2015 Incentive Award Plan, 2017 Employment Inducement Incentive Award Plan and Livongo Acquisition Incentive Award Plan (together with the 2023 Plans, collectively, the “Plans”) also provided for the issuance of such awards. The Company had 8,768,512 shares available for grant under the 2023 Plans at March 31, 2024. All stock-based awards to employees are measured based on the grant-date fair value, or replacement grant date fair value in relation to the Livongo transaction, and are generally recognized on a straight line basis in the Company’s Condensed Consolidated Statements of Operations over the period during which the employee is required to perform services in exchange for the award (generally requiring a four-year vesting period for each stock option and a three-year vesting period for each restricted stock unit (“RSU”)). The Company recognizes the forfeiture of stock-based awards as they occur. Stock Options Options issued under the Plans are exercisable for periods not to exceed 10 years, and vest and contain such other terms and conditions as specified in the applicable award document. Options to buy common stock are issued under the Plans, with exercise prices equal to the closing price of shares of the Company’s common stock on the New York Stock Exchange on the date of award. Stock option activity under the Plans was as follows (in thousands, except share and per share amounts and years): Number of Weighted- Weighted- Aggregate Balance at December 31, 2023 4,182,187 $ 27.37 5.26 $ 13,732 Stock option grants 32,477 $ 20.66 N/A Stock options exercised (24,072) $ 5.45 N/A $ 291 Stock options forfeited (148,705) $ 39.78 N/A Balance at March 31, 2024 4,041,887 $ 27.13 4.75 $ 5,669 Vested or expected to vest at March 31, 2024 4,041,887 $ 27.13 4.75 $ 5,669 Exercisable at March 31, 2024 3,274,003 $ 26.43 3.83 $ 5,669 The total grant-date fair value of stock options granted during the three months ended March 31, 2024 and 2023 were $0.4 million and $0.2 million, respectively. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The assumptions used are determined as follows: Volatility. The expected volatility was derived from the historical stock volatility of the Company’s stock over a period equivalent to the expected term of the stock option grants. Expected Term. The expected term represents the period that the stock-based awards are expected to be outstanding. When establishing the expected term assumption, the Company utilizes historical data. Risk-Free Interest Rate. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with terms similar to the expected term on the options. Dividend Yield. The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future and, therefore, it used an expected dividend yield of zero. The fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions and fair value per share: Three Months Ended 2024 2023 Volatility 67.86% - 67.94% 65.58% Expected term (in years) 4.3 4.3 Risk-free interest rate 3.85% - 3.90% 4.07% Dividend yield 0% 0% Weighted-average fair value of underlying stock options $11.55 $12.85 For the three months ended March 31, 2024 and 2023, the Company recorded stock-based compensation expense related to stock options granted of $1.7 million and $2.2 million, respectively. As of March 31, 2024, the Company had $11.2 million in unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over a weighted-average period of approximately 2.0 years. Restricted Stock Units The fair value of RSUs is determined on the date of grant. The Company records compensation expense in the Consolidated Statements of Operations on a straight-line basis over the vesting period for RSUs. The vesting period for employees and members of the Board of Directors ranges from one RSU activity under the Plans was as follows: RSUs Weighted-Average Balance at December 31, 2023 9,452,412 $ 34.70 Granted 4,447,425 $ 15.09 Vested and issued (2,451,940) $ 39.04 Forfeited (571,190) $ 33.54 Balance at March 31, 2024 10,876,707 $ 25.82 Vested and unissued at March 31, 2024 43,118 $ 56.25 Non-vested at March 31, 2024 10,833,589 $ 25.70 The total grant-date fair value of RSUs granted during the three months ended March 31, 2024 and 2023, was $67.1 million and $169.1 million, respectively. For the three months ended March 31, 2024 and 2023, the Company recorded stock-based compensation expense related to RSUs of $37.3 million and $38.8 million, respectively. As of March 31, 2024, the Company had $246.8 million in unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a weighted-average period of approximately 2.0 years. Performance Stock Units Stock-based compensation costs associated with the Company’s RSUs subject to performance criteria (“PSUs”) are initially determined using the fair market value of the Company’s common stock on the date the awards are granted (service inception date). The vesting of these PSUs is subject to certain performance conditions and a service requirement ranging from one The ultimate number of PSUs that are issued to an employee is the result of the actual performance of the Company at the end of the performance period compared to the performance targets and generally r anges from 0% to 200% of the initial grant. Stock compensation expense for PSUs is recognized on an accelerated tranche by tranche basis for performance-based awards. PSU activity under the Plans was as follows: Shares Weighted-Average Balance at December 31, 2023 1,452,387 $ 36.82 Granted 1,359,651 $ 15.03 Vested and issued (179,764) $ 56.25 Forfeited (23,240) $ 26.88 Performance adjustment (1) (241,073) Balance at March 31, 2024 2,367,961 $ 22.73 Vested and unissued at March 31, 2024 — $ — Non-vested at March 31, 2024 2,367,961 $ 22.73 (1) Based on the Company's 2023 results, PSUs were attained at rates ranging from 0% to 85.2% of the target award. The total grant-date fair value of PSUs granted during the three months ended March 31, 2024 and 2023 was $20.4 million and $30.3 million, respectively. For the three months ended March 31, 2024 and 2023, the Company recorded stock-based compensation expense related to PSUs of $2.6 million and $3.4 million, respectively. As of March 31, 2024, the Company had $30.7 million in unrecognized compensation cost related to non-vested PSUs, which is expected to be recognized over a weighted-average period of approximately 2.2 years. Employee Stock Purchase Plan In July 2015, the Company adopted the 2015 Employee Stock Purchase Plan (“ESPP”) in connection with its initial public offering. At the Company’s 2023 annual meeting of stockholders, the Company’s stockholders approved an amendment to the ESPP to increase the number of shares of the Company’s common stock available for issuance under the ESPP by 3,000,000. A total of 4,113,343 shares of common stock have been reserved for issuance under this plan as of March 31, 2024. The Company’s ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Under the ESPP, the Company may specify offerings with durations of not more than 27 months and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of its common stock will be purchased for employees participating in the offering. An offering may be terminated under certain circumstances. The price at which the stock is purchased is equal to the lower of 85% of the fair market value of the common stock at the beginning of an offering period or on the date of purchase. During the three months ended March 31, 2024 and 2023, the Company did not issue any shares under the ESPP. As of March 31, 2024, 2,800,781 shares remained available for issuance. For the three months ended March 31, 2024 and 2023, the Company recorded stock-based compensation expense related to the ESPP of $0.8 million and $1.6 million, respectively. As of March 31, 2024, the Company had $0.3 million in unrecognized compensation cost related to the ESPP, which is expected to be recognized over a weighted-average period of approximately 0.1 years. Total compensation costs for stock-based awards were recorded as follows (in thousands): Three Months Ended 2024 2023 Cost of revenue (exclusive of depreciation and amortization, which are shown separately) $ 1,394 $ 1,353 Advertising and marketing 3,789 3,126 Sales 7,967 8,075 Technology and development 9,299 12,729 General and administrative 19,876 20,755 Total stock-based compensation expense 42,325 46,038 Capitalized stock-based compensation 3,897 4,596 Total stock-based compensation $ 46,222 $ 50,634

Provision for Income Taxes

Provision for Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Provision for Income Taxes	Provision for Income TaxesThe Company recorded income tax expense of $2.7 million and $0.7 million for the three months ended March 31, 2024 and 2023, respectively. The tax expenses recorded were the result of the tax shortfall associated with the stock-based compensation awards that vested in the year.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments The Company has contractual obligations to make future payments related to its outstanding convertible senior notes, which are presented in Note 9. Convertible Senior Notes, and its long-term operating leases, which are presented in Note 10. Leases. Legal Matters From time to time, Teladoc Health is involved in various litigation matters arising in the normal course of business, including the matters described below. The Company consults with legal counsel on those issues related to litigation and seeks input from other experts and advisors with respect to such matters. Estimating the probable losses or a range of probable losses resulting from litigation, government actions, and other legal proceedings is inherently difficult and requires an extensive degree of judgment, particularly where the matters involve indeterminate claims for monetary damages, may involve discretionary amounts, present novel legal theories, are in the early stages of the proceedings, or are subject to appeal. Whether any losses, damages, or remedies ultimately resulting from such matters could reasonably have a material effect on the Company’s business, financial condition, results of operations, or cash flows will depend on a number of variables, including, for example, the timing and amount of such losses or damages (if any) and the structure and type of any such remedies. As of the date of these financial statements, Teladoc Health’s management does not expect any litigation matter to have a material adverse impact on its business, financial condition, results of operations, or cash flows. On June 6, 2022, a purported securities class action complaint (Schneider v. Teladoc Health, Inc., et. al.) was filed in the U.S. District Court for the Southern District of New York against the Company and certain of the Company’s officers. The complaint was brought on behalf of a purported class consisting of all persons or entities who purchased or otherwise acquired shares of the Company’s common stock during the period October 28, 2021 through April 27, 2022. The complaint asserted violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder based on allegedly false or misleading statements and omissions with respect to, among other things, the Company’s business, operations, and prospects. The complaint seeks certification as a class action and unspecified compensatory damages plus interest and attorneys’ fees. On August 2, 2022, a duplicative purported securities class action complaint (De Schutter v. Teladoc Health, Inc., et.al.) was filed in the U.S. District Court for the Eastern District of New York. The claims and parties in De Schutter were substantially similar to those in Schneider. The De Schutter case was transferred on consent to the Southern District court, and the Schneider and De Schutter actions have now been consolidated under the caption In re Teladoc Health, Inc. Securities Litigation. On August 23, 2022, the court appointed Leadersel Innotech ESG as lead plaintiff pursuant to the Private Securities Litigation Reform Act of 1995. The lead plaintiff filed an amended complaint on September 30, 2022, on behalf of a purported class consisting of all persons or entities who purchased or otherwise acquired shares of the Company’s common stock during the period February 24, 2021 to July 27, 2022, and filed a second amended complaint on December 6, 2022, on behalf of a purported class consisting of all persons or entities who purchased or otherwise acquired shares of the Company’s common stock during the period February 11, 2021 to July 27, 2022. On July 5, 2023, the court granted the defendants’ motion to dismiss the complaint. On November 17, 2023, the lead plaintiff filed an appeal in the United States Court of Appeals for the Second Circuit. The Company believes that it has substantial defenses, and the Company and its named officers intend to defend the appeal and any further proceedings in the lawsuit vigorously. On August 9, 2022, a verified shareholder derivative complaint (Vaughn v. Teladoc Health, Inc., et.al.) was filed in the U.S. District Court for the Southern District of New York against the Company as a nominal defendant and certain of the Company’s officers and directors. The complaint asserts violations of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, breach of fiduciary duty, aiding and abetting breach of fiduciary duty, unjust enrichment, and waste of corporate assets in connection with factual assertions similar to those in the purported securities class action complaints described above. The complaint seeks damages to the Company allegedly sustained as a result of the acts and omissions of the named officers and directors and seeks an order directing the Company to reform and improve the Company’s corporate governance. On September 6, 2022, a duplicative verified stockholder derivative complaint (Hendry v. Teladoc Health, Inc., et. al.) was filed in the U.S. District Court for the Southern District of New York. The claims and parties in Hendry were substantially similar to those in Vaughn. The Vaughn and Hendry actions have now been consolidated under the caption In re Teladoc Stockholder Derivative Litigation, and a consolidated complaint was filed on November 29, 2022. The consolidated complaint also asserts violations of Section 14(a) of the Securities Exchange Act of 1934. The parties subsequently stipulated to transfer the action to the U.S. District Court for the District of Delaware, and on December 22, 2022 the parties agreed, and the Court ordered, to stay all proceedings until final resolution, including exhaustion of appeals, of the motion to dismiss filed in the purported securities class action complaint described above. On July 30, 2020, the Company’s subsidiary BetterHelp, Inc. (“BetterHelp”) received a Civil Investigative Demand from the U.S. Federal Trade Commission (“FTC”) as part of its non-public investigation to determine whether BetterHelp engaged in unfair business practices in violation of the Federal Trade Commission Act. In March 2023, BetterHelp and the FTC entered into a tentative settlement of all claims arising from the FTC’s investigation and agreed to a consent order that required the Company to make a $7.8 million payment to the FTC. The settlement, including the consent order, received final approval from the FTC on July 14, 2023. There have been multiple putative class-action litigations filed against BetterHelp in connection with the above-referenced FTC settlement and consent order. The actions have been filed in California federal and state courts and in Canada. The cases are substantially similar, involving allegations of misleading patients as to BetterHelp’s use of patient data and associated alleged violations of law involving privacy, advertising, contract, and tort. The Company believes that it has substantial defenses, and the Company intends to defend the lawsuits vigorously. On February 13, 2023, Data Health Partners, Inc. (“Data Health Partners”) filed a lawsuit against the Company in the U.S. District Court for the District of Delaware alleging that certain of the Company’s products, including its blood glucose meter, infringe upon certain patents held by Data Health Partners and seeking unspecified damages, attorney’s fees and costs. The Company believes that it has substantial defenses, and the Company intends to defend the lawsuit vigorously.

Segments

Segments	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Segments	Segments ASC Subtopic 280-10, “Segment Reporting,” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and assess performance. The Company’s Chief Executive Officer is the CODM and is responsible for reviewing financial information presented on a segment basis for purposes of making operating decisions and assessing financial performance. The CODM measures and evaluates segments based on segment operating revenues together with Adjusted EBITDA. The Company excludes the following items from segment Adjusted EBITDA: provision for income taxes; other expense (income), net; interest income; interest expense; depreciation of property and equipment; amortization of intangible assets; stock-based compensation; restructuring costs; and acquisition, integration and transformation charges. Although these amounts are excluded from segment Adjusted EBITDA, they are included in reported consolidated net loss and are included in the reconciliation that follows. The Company’s computation of segment Adjusted EBITDA may not be comparable to other similarly titled metrics computed by other companies because all companies do not calculate segment Adjusted EBITDA in the same fashion. Operating revenues and expenses directly associated with each segment are included in determining its operating results. Other expenses that are not directly attributable to a particular segment are based upon allocation methodologies, including the following: revenue, headcount, time and other relevant usage measures, and/or a combination of such. The Company has two reportable segments: Teladoc Health Integrated Care and BetterHelp. The Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment includes virtual therapy and other wellness services provided on a global basis which are predominantly marketed and sold on a direct-to-consumer basis. The CODM does not review any information regarding total assets on a segment basis. Segments do not record intersegment revenues, and, accordingly, there is none to be reported. The accounting policies for segment reporting are the same as for the Company as a whole. The following table presents revenues by segment (in thousands): Three Months Ended 2024 2023 Teladoc Health Integrated Care $ 377,111 $ 349,972 BetterHelp 269,020 279,272 Total Consolidated Revenue $ 646,131 $ 629,244 The following table presents Adjusted EBITDA by segment (in thousands): Three Months Ended 2024 2023 Teladoc Health Integrated Care $ 47,674 $ 35,127 BetterHelp 15,466 17,638 Total Consolidated Adjusted EBITDA $ 63,140 $ 52,765 The following table presents a reconciliation of segment profitability (Adjusted EBITDA) to consolidated net loss (in thousands): Three Months Ended 2024 2023 Teladoc Health Integrated Care $ 47,674 $ 35,127 BetterHelp 15,466 17,638 Total consolidated Adjusted EBITDA 63,140 52,765 Less adjustments to reconcile to GAAP net loss Interest income (13,942) (8,911) Interest expense 5,649 5,263 Other expense (income), net 370 (4,907) Amortization of intangible assets 95,057 66,860 Depreciation of property and equipment 2,834 2,923 Stock-based compensation 42,325 46,038 Acquisition, integration, and transformation costs 373 5,944 Restructuring costs 9,673 8,102 Loss before provision for income taxes (79,199) (68,547) Provision for income taxes 2,690 681 Net loss $ (81,889) $ (69,228) Geographic data for long-lived assets (representing property and equipment, net) were as follows (in thousands): As of March 31, As of December 31, United States $ 26,519 $ 28,096 Other 3,031 3,936 Total long-lived assets $ 29,550 $ 32,032

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event As previously reported in a Form 8-K filed with the SEC on April 5, 2024, Teladoc Health’s Chief Executive Officer departed, effective immediately, and is eligible to receive the separation benefits pursuant to his employment agreement, subject to the execution and nonrevocation of a release of claims and other conditions of his employment agreement. In the three months ending June 30, 2024, the Company expects to recognize approximately $6.4 million of costs related to the separation, with $1.2 million for salary continuation and 2024 pro-rated annual bonus and $5.2 million for stock-based compensation, representing the impact of accelerations, modifications, and forfeitures.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net loss	$ (81,889)	$ (69,228)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Vidya Raman-Tangella [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	On March 1, 2024, Vidya Raman-Tangella, our Chief Medical Officer, adopted a Rule 10b5-1 trading plan. Dr. Raman-Tangella's trading plan provides for the sale of up to 45,675 shares of our common stock through June 2025.
Name	Vidya Raman-Tangella
Title	Chief Medical Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	March 1, 2024
Arrangement Duration	486 days
Aggregate Available	45,675

Basis of Presentation and Pri_2

Basis of Presentation and Principles of Consolidation (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements for t he three months ended March 31, 2024 and 2023, in the opinion of management, reflect all adjustments (consisting of normal recurring ac cruals) necessary for a fair presentation of the Condensed Consolidated Results of Operations, financial position and cash flows of Teladoc Health for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States (“U.S.”) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended December 31, 2023 (the “2023 Form 10-K”), which includes a complete set of footnote disclosures, including the Company’s significant accounting policies. These consolidated financial statements include the results of Teladoc Health, as well as two professional associations and 10 professional corporations (collectively, the “THMG Association”). Teladoc Health Medical Group, P.A., formerly Teladoc Physicians, P.A. (“THMG”), is party to a Services Agreement by and among it and the professional associations and professional corporations pursuant to which each professional association and professional corporation provides services to THMG. Each professional association and professional corporation is established pursuant to the requirements of its respective domestic jurisdiction governing the corporate practice of medicine.
Principles of Consolidation	The Company holds a variable interest in the THMG Association, which contracts with physicians and other health professionals in order to provide services to Teladoc Health. The THMG Association is considered a variable interest entity (“VIE”) since it does not have sufficient equity to finance its activities without additional subordinated financial support. An enterprise having a controlling financial interest in a VIE must consolidate the VIE if it has both power and benefits—that is, it has (1) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). The Company has the power and rights to control all activities of the THMG Association and funds and absorbs all losses of the VIE and appropriately consolidates the THMG Association.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business and economic factors, and various other assumptions that the Company believes are necessary to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s condensed consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves. The Company believes that estimates used in the preparation of these condensed consolidated financial statements are reasonable; however, actual results could differ materially from these estimates. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in the Condensed Consolidated Statements of Operations; if material, the effects of changes in estimates are disclosed in the Notes to Unaudited Condensed Consolidated Financial Statements. Significant estimates and assumptions by management affect areas including the value and useful life of long-lived assets (including intangible assets), the capitalization and amortization of software development costs, deferred device and contract costs, allowances for sales and for doubtful accounts, and the accounting for business combinations. Other significant areas include revenue recognition (including performance guarantees), the accounting for income taxes, contingencies, litigation and related legal accruals, the accounting for stock-based compensation awards, and other items as described in Note 2. “Basis of Presentation and Principles of Consolidation" in the Summary of Significant Accounting policies in the 2023 Form 10-K and as may be updated in this Quarterly Report in Note 2. “Basis of Presentation and Principles of Consolidation."
Fair Value Measurements	Fair Value Measurements The carrying value of the Company’s cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximates fair value due to their short-term nature. A financial instrument’s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value: Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2—Include other inputs that are directly or indirectly observable in the marketplace. Level 3—Unobservable inputs that are supported by little or no market activity. The Company measures its cash equivalents at fair value on a recurring basis. The Company classifies its cash equivalents within Level 1 because they are valued using observable inputs that reflect quoted prices for identical assets in active markets and quoted prices directly in active markets.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform to the current year presentation.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, “Segment Reporting (Topic 280)—Improvements to Report Segment Disclosures” which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses so that investors can better understand an entity’s overall performance. The amendments are effective for annual reporting periods beginning after December 15, 2023, and interim periods, beginning after December 15, 2024, with early adoption permitted. The provisions of ASU 2023-07 are to be applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company is currently evaluating the impact of adopting ASU 2023-07 on its financial disclosures. In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvement to Income Tax Disclosures" to enhance the transparency and decision usefulness of income tax disclosures through expansion of disclosures in an entity’s income tax rate reconciliation table and regarding cash taxes paid both in the U.S. and foreign jurisdictions. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 on a prospective basis with early adoption permitted. The Company is currently evaluating the impact of ASU 2023-09 on its financial disclosures. In March 2024, the SEC issued Release Nos. 33-11275; 34-99678 "The Enhancement and Standardization of Climate-Related Disclosures for Investors" to improve the consistency, comparability, and reliability of disclosures on the financial effects of climate-related risks on a registrant's operations and how it manages these risks. The compliance date for this release was scheduled to be fiscal year 2025 for large accelerated filers. On April 4, 2024, the SEC voluntarily stayed implementation of this new rule pending judicial review. The Company is currently analyzing the impact that the new climate-related rules will have on its consolidated financial statements.

Revenue, Deferred Revenue, an_2

Revenue, Deferred Revenue, and Deferred Device and Contract Costs (Tables)	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table presents the Company’s revenues disaggregated by revenue source and also by geography (in thousands): Three Months Ended 2024 2023 Revenue by Type Access fees $ 557,174 $ 550,870 Other 88,957 78,374 Total Revenue $ 646,131 $ 629,244 Revenue by Geography U.S. Revenue $ 547,600 $ 541,662 International Revenue 98,531 87,582 Total Revenue $ 646,131 $ 629,244
Deferred Revenue Activities	The following table summarizes deferred revenue activities for the periods presented (in thousands): Three Months Ended 2024 2023 Beginning balance $ 109,283 $ 113,786 Cash collected 63,061 67,242 Revenue recognized (56,113) (61,697) Ending balance $ 116,231 $ 119,331
Deferred Device and Contract Costs	Deferred device and contract costs are classified as a component of prepaid expenses and other current assets or other assets, depending on term, and consisted of the following (in thousands): As of March 31, As of December 31, Deferred device and contract costs, current $ 34,199 $ 32,703 Deferred device and contract costs, noncurrent 17,344 17,573 Total deferred device and contract costs $ 51,543 $ 50,276 Deferred device and contract costs were as follows (in thousands): Deferred Device and Contract Costs Beginning balance as of December 31, 2023 $ 50,276 Additions 12,239 Cost of revenue recognized (10,972) Ending balance as of March 31, 2024 $ 51,543

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Schedule of inventories	Inventories consisted of the following (in thousands): As of March 31, As of December 31, Raw materials and purchased parts $ 11,529 $ 9,338 Work in process 678 299 Finished goods 20,061 19,876 Total inventories $ 32,268 $ 29,513

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following (in thousands): As of March 31, As of December 31, Prepaid expenses $ 85,477 $ 65,651 Deferred device and contract costs, current 34,199 32,703 Other receivables 13,559 12,640 Other current assets 8,534 7,443 Total prepaid expenses and other current assets $ 141,769 $ 118,437

Goodwill (Tables)

Goodwill (Tables)	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Goodwill	Goodwill consisted of the following (in thousands): Teladoc Health Integrated BetterHelp Total Balance as of December 31, 2023 and March 31, 2024 $ — $ 1,073,190 $ 1,073,190

Intangible Assets, Net and Ce_2

Intangible Assets, Net and Certain Cloud Computing Costs (Tables)	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	Intangible assets, net consisted of the following (in thousands, except years): Useful Gross Value Accumulated Net Carrying Weighted March 31, 2024 Client relationships 2 to 20 years $ 1,458,261 $ (415,879) $ 1,042,382 12.3 Trademarks 2 to 15 years 325,022 (214,080) 110,942 6.6 Software 3 to 5 years 489,041 (191,956) 297,085 2.4 Acquired technology 4 to 7 years 341,741 (177,912) 163,829 3.5 Intangible assets, net $ 2,614,065 $ (999,827) $ 1,614,238 9.2 December 31, 2023 Client relationships 2 to 20 years $ 1,460,857 $ (391,196) $ 1,069,661 12.5 Trademarks 2 to 15 years 325,479 (189,330) 136,149 6.9 Software 3 to 5 years 456,583 (161,108) 295,475 2.5 Acquired technology 4 to 7 years 341,814 (165,318) 176,496 3.7 Intangible assets, net $ 2,584,733 $ (906,952) $ 1,677,781 9.3
Amortization of Intangible Assets Expense by Components	The following table presents the Company's amortization of intangible assets expense by component (in thousands): Three Months Ended 2024 2023 Amortization of acquired intangibles $ 64,181 $ 50,259 Amortization of capitalized software development costs 30,876 16,601 Amortization of intangible assets expense $ 95,057 $ 66,860
Periodic Amortization of Intangible Assets to be Charged to Expense over the Remaining Life of Intangible Assets	Periodic amortization of intangible assets that will be charged to expense over the remaining life of the intangible assets as of March 31, 2024 was as follows (in thousands): Years Ending December 31, 2024 $ 272,784 2025 280,727 2026 223,039 2027 163,836 2028 and thereafter 673,852 $ 1,614,238

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities As of March 31, As of December 31, Client performance guarantees and accrued rebates $ 36,282 $ 36,934 Marketing and advertising 38,724 34,427 Consulting fees/provider fees 16,443 16,416 Franchise, sales and other taxes 12,931 12,933 Operating lease liabilities – current 10,744 10,752 Professional fees 10,137 9,910 Information technology 7,968 7,605 Insurance 6,530 5,777 Interest payable 5,812 1,481 Income tax payable 4,127 621 Staff augmentation 3,532 4,287 Lease abandonment obligation - current 3,489 3,800 Other 42,699 33,691 Total $ 199,418 $ 178,634

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Debt Outstanding	The following table presents certain terms of the Notes that were outstanding as of March 31, 2024: 2027 Notes 2025 Notes Livongo Notes Principal Amount Outstanding as of March 31, 2024 (in millions) $ 1,000.0 $ 0.7 $ 550.0 Interest Rate Per Year 1.25 % 1.375 % 0.875 % Fair Value as of March 31, 2024 (in millions) (1) $ 843.0 $ 0.2 $ 519.8 Fair Value as of December 31, 2023 (in millions) (1) $ 822.0 $ 0.3 $ 513.7 Maturity Date June 1, 2027 May 15, 2025 June 1, 2025 Optional Redemption Date June 5, 2024 May 22, 2022 June 5, 2023 Conversion Date December 1, 2026 November 15, 2024 March 1, 2025 Conversion Rate Per $1,000 Principal Amount as of March 31, 2024 4.1258 18.6621 13.9400 Remaining Contractual Life as of March 31, 2024 3.2 years 1.1 years 1.2 years (1) The Company estimates the fair value of its Notes utilizing market quotations for debt that have quoted prices in active markets. Since the Notes do not trade on a daily basis in an active market, the fair value estimates are based on market observable inputs based on borrowing rates currently available for debt with similar terms and average maturities. The Notes would be classified as Level 2 within the fair value hierarchy, as defined in Note 2. “Basis of Presentation and Principles of Consolidation.”
Net Carrying Values of Debt	The net carrying values of the Notes consisted of the following (in thousands): As of March 31, As of December 31, 2027 Notes Principal $ 1,000,000 $ 1,000,000 Less: Debt discount, net (1) (11,175) (12,033) Net carrying amount 988,825 987,967 2025 Notes Principal 725 725 Less: Debt discount, net (1) (4) (4) Net carrying amount 721 721 Livongo Notes Principal 550,000 550,000 Less: Debt discount, net (1) — — Net carrying amount 550,000 550,000 Total net carrying amount $ 1,539,546 $ 1,538,688 (1) Included in the accompanying Condensed Consolidated Balance Sheets within convertible senior notes and amortized to interest expense over the expected life of the Notes using the effective interest rate method.
Total Interest Expense Recognized Related to Debt	The following table sets forth total interest expense recognized related to the Notes (in thousands): Three Months Ended 2027 Notes 2024 2023 Contractual interest expense $ 3,125 $ 3,125 Amortization of debt discount 858 844 Total $ 3,983 $ 3,969 Effective interest rate 1.6 % 1.6 % Three Months Ended 2025 Notes 2024 2023 Contractual interest expense $ 2 $ 2 Amortization of debt discount 1 1 Total $ 3 $ 3 Effective interest rate 1.8 % 1.6 % Three Months Ended Livongo Notes 2024 2023 Contractual interest expense $ 1,203 $ 1,203 Amortization of debt discount — — Total $ 1,203 $ 1,203 Effective interest rate 0.9 % 1.3 %

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Future Minimum Lease Payments	The future minimum lease payments under non-cancelable operating leases were as follows (in thousands): Operating Leases: As of March 31, 2024 $ 9,979 2025 12,260 2026 11,101 2027 8,088 2028 5,918 2029 and thereafter 12,985 Total future minimum payments 60,331 Less: imputed interest (9,616) Present value of lease liabilities $ 50,715 Accrued expenses and other current liabilities $ 10,744 Operating lease liabilities, net of current portion $ 39,971

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Mar. 31, 2024
Restructuring and Related Activities [Abstract]
Accrual and Charges Incurred Related to Restructuring	The table below summarizes the accrual and charges incurred and cash payments made with respect to the Company's restructurings, with the severance related portion included in the line item "Accrued compensation" and the lease termination and other related portion included in the line item "Accrued expenses and other current liabilities" in the Company's Condensed Consolidated Balance Sheet as of March 31, 2024 (in thousands): Restructuring Plan Severance Lease Termination Other (1) Total Accrued Balance, December 31, 2023 $ — $ 3,800 $ — $ 3,800 Additional expenses (recoveries) 6,957 (14) 2,730 9,673 Cash payments (6,769) (297) (953) (8,019) Accrued Balance, March 31, 2024 $ 188 $ 3,489 $ 1,777 $ 5,454

Common Stock and Stockholders_2

Common Stock and Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock Option Activity	Stock option activity under the Plans was as follows (in thousands, except share and per share amounts and years): Number of Weighted- Weighted- Aggregate Balance at December 31, 2023 4,182,187 $ 27.37 5.26 $ 13,732 Stock option grants 32,477 $ 20.66 N/A Stock options exercised (24,072) $ 5.45 N/A $ 291 Stock options forfeited (148,705) $ 39.78 N/A Balance at March 31, 2024 4,041,887 $ 27.13 4.75 $ 5,669 Vested or expected to vest at March 31, 2024 4,041,887 $ 27.13 4.75 $ 5,669 Exercisable at March 31, 2024 3,274,003 $ 26.43 3.83 $ 5,669
Assumptions Used for Estimate of Fair Value of Options	The fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions and fair value per share: Three Months Ended 2024 2023 Volatility 67.86% - 67.94% 65.58% Expected term (in years) 4.3 4.3 Risk-free interest rate 3.85% - 3.90% 4.07% Dividend yield 0% 0% Weighted-average fair value of underlying stock options $11.55 $12.85
Restricted Stock Units Activity	RSU activity under the Plans was as follows: RSUs Weighted-Average Balance at December 31, 2023 9,452,412 $ 34.70 Granted 4,447,425 $ 15.09 Vested and issued (2,451,940) $ 39.04 Forfeited (571,190) $ 33.54 Balance at March 31, 2024 10,876,707 $ 25.82 Vested and unissued at March 31, 2024 43,118 $ 56.25 Non-vested at March 31, 2024 10,833,589 $ 25.70
Performance-Based Units Activity	PSU activity under the Plans was as follows: Shares Weighted-Average Balance at December 31, 2023 1,452,387 $ 36.82 Granted 1,359,651 $ 15.03 Vested and issued (179,764) $ 56.25 Forfeited (23,240) $ 26.88 Performance adjustment (1) (241,073) Balance at March 31, 2024 2,367,961 $ 22.73 Vested and unissued at March 31, 2024 — $ — Non-vested at March 31, 2024 2,367,961 $ 22.73 (1) Based on the Company's 2023 results, PSUs were attained at rates ranging from 0% to 85.2% of the target award.
Total Compensation Costs for Stock-Based Awards	Total compensation costs for stock-based awards were recorded as follows (in thousands): Three Months Ended 2024 2023 Cost of revenue (exclusive of depreciation and amortization, which are shown separately) $ 1,394 $ 1,353 Advertising and marketing 3,789 3,126 Sales 7,967 8,075 Technology and development 9,299 12,729 General and administrative 19,876 20,755 Total stock-based compensation expense 42,325 46,038 Capitalized stock-based compensation 3,897 4,596 Total stock-based compensation $ 46,222 $ 50,634

Segments (Tables)

Segments (Tables)	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Segment Reporting Information	The following table presents revenues by segment (in thousands): Three Months Ended 2024 2023 Teladoc Health Integrated Care $ 377,111 $ 349,972 BetterHelp 269,020 279,272 Total Consolidated Revenue $ 646,131 $ 629,244 The following table presents Adjusted EBITDA by segment (in thousands): Three Months Ended 2024 2023 Teladoc Health Integrated Care $ 47,674 $ 35,127 BetterHelp 15,466 17,638 Total Consolidated Adjusted EBITDA $ 63,140 $ 52,765
Reconciliation of Segment Profitability Adjusted EBITDA to Consolidated Net Loss	The following table presents a reconciliation of segment profitability (Adjusted EBITDA) to consolidated net loss (in thousands): Three Months Ended 2024 2023 Teladoc Health Integrated Care $ 47,674 $ 35,127 BetterHelp 15,466 17,638 Total consolidated Adjusted EBITDA 63,140 52,765 Less adjustments to reconcile to GAAP net loss Interest income (13,942) (8,911) Interest expense 5,649 5,263 Other expense (income), net 370 (4,907) Amortization of intangible assets 95,057 66,860 Depreciation of property and equipment 2,834 2,923 Stock-based compensation 42,325 46,038 Acquisition, integration, and transformation costs 373 5,944 Restructuring costs 9,673 8,102 Loss before provision for income taxes (79,199) (68,547) Provision for income taxes 2,690 681 Net loss $ (81,889) $ (69,228)
Geographic Data for Long-Lived Assets	Geographic data for long-lived assets (representing property and equipment, net) were as follows (in thousands): As of March 31, As of December 31, United States $ 26,519 $ 28,096 Other 3,031 3,936 Total long-lived assets $ 29,550 $ 32,032

Basis of Presentation and Pri_3

Basis of Presentation and Principles of Consolidation (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($) professionalCorporation professionalAssociation	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Variable interest entity
Number of professional associations consolidated as VIEs | professionalAssociation	2
Number of professional corporations consolidated as VIEs | professionalCorporation	10
Revenue	$ 646,131	$ 629,244
Net loss	81,889	69,228
Assets	4,320,756		$ 4,392,369
Stockholders' deficit	2,288,898	2,291,226	2,326,073	$ 2,307,745
Variable Interest Entity, Primary Beneficiary
Variable interest entity
Revenue	70,000	61,600
Net loss	0	$ 0
Assets	21,400		20,600
Liabilities	70,000		69,200
Stockholders' deficit	$ 48,600		$ 48,600

Revenue, Deferred Revenue, an_3

Revenue, Deferred Revenue, and Deferred Device and Contract Costs - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Revenue	$ 646,131	$ 629,244
U.S. Revenue
Disaggregation of Revenue [Line Items]
Revenue	547,600	541,662
International Revenue
Disaggregation of Revenue [Line Items]
Revenue	98,531	87,582
Access fees
Disaggregation of Revenue [Line Items]
Revenue	557,174	550,870
Other
Disaggregation of Revenue [Line Items]
Revenue	$ 88,957	$ 78,374

Revenue, Deferred Revenue, an_4

Revenue, Deferred Revenue, and Deferred Costs and Other - Deferred Revenue Activities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Contract With Customer Liability [Roll Forward]
Beginning balance	$ 109,283	$ 113,786
Cash collected	63,061	67,242
Revenue recognized	(56,113)	(61,697)
Ending balance	$ 116,231	$ 119,331

Revenue, Deferred Revenue, an_5

Revenue, Deferred Revenue, and Deferred Device and Contract Costs - Narrative (Details) $ in Millions	Mar. 31, 2024 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue recognized, performance obligation	$ 94
Period of performance obligation	9 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue recognized, performance obligation	$ 17.3
Period of performance obligation	1 year

Revenue, Deferred Revenue, an_6

Revenue, Deferred Revenue, and Deferred Device and Contract Costs - Deferred Device and Contract Costs (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Deferred device and contract costs, current	$ 34,199	$ 32,703
Deferred device and contract costs, noncurrent	17,344	17,573
Total deferred device and contract costs	$ 51,543	$ 50,276

Revenue, Deferred Revenue, an_7

Revenue, Deferred Revenue, and Deferred Device and Contract Costs - Deferred Device and Contract Costs Rollforward (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Deferred Device Cost And Other [Roll Forward]
Beginning balance as of December 31, 2023	$ 50,276
Additions	12,239
Cost of revenue recognized	(10,972)
Ending balance as of March 31, 2024	$ 51,543

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials and purchased parts	$ 11,529	$ 9,338
Work in process	678	299
Finished goods	20,061	19,876
Total inventories	$ 32,268	$ 29,513

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses	$ 85,477	$ 65,651
Deferred device and contract costs, current	34,199	32,703
Other receivables	13,559	12,640
Other current assets	8,534	7,443
Total prepaid expenses and other current assets	$ 141,769	$ 118,437

Goodwill - Summary of Goodwill

Goodwill - Summary of Goodwill (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Goodwill [Line Items]
Goodwill	$ 1,073,190	$ 1,073,190
Teladoc Health Integrated Care
Goodwill [Line Items]
Goodwill	0	0
BetterHelp
Goodwill [Line Items]
Goodwill	$ 1,073,190	$ 1,073,190

Intangible Assets, Net and Ce_3

Intangible Assets, Net and Certain Cloud Computing Costs - Intangible Assets, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Gross Value	$ 2,614,065	$ 2,584,733
Accumulated Amortization	(999,827)	(906,952)
Net Carrying Value	$ 1,614,238	$ 1,677,781
Weighted Average
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Life (Years)	9 years 2 months 12 days	9 years 3 months 18 days
Client relationships
Finite-Lived Intangible Assets [Line Items]
Gross Value	$ 1,458,261	$ 1,460,857
Accumulated Amortization	(415,879)	(391,196)
Net Carrying Value	$ 1,042,382	$ 1,069,661
Client relationships | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful Life	2 years	2 years
Client relationships | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful Life	20 years	20 years
Client relationships | Weighted Average
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Life (Years)	12 years 3 months 18 days	12 years 6 months
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Value	$ 325,022	$ 325,479
Accumulated Amortization	(214,080)	(189,330)
Net Carrying Value	$ 110,942	$ 136,149
Trademarks | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful Life	2 years	2 years
Trademarks | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful Life	15 years	15 years
Trademarks | Weighted Average
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Life (Years)	6 years 7 months 6 days	6 years 10 months 24 days
Software
Finite-Lived Intangible Assets [Line Items]
Gross Value	$ 489,041	$ 456,583
Accumulated Amortization	(191,956)	(161,108)
Net Carrying Value	$ 297,085	$ 295,475
Software | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful Life	3 years	3 years
Software | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful Life	5 years	5 years
Software | Weighted Average
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Life (Years)	2 years 4 months 24 days	2 years 6 months
Acquired technology
Finite-Lived Intangible Assets [Line Items]
Gross Value	$ 341,741	$ 341,814
Accumulated Amortization	(177,912)	(165,318)
Net Carrying Value	$ 163,829	$ 176,496
Acquired technology | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful Life	4 years	4 years
Acquired technology | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful Life	7 years	7 years
Acquired technology | Weighted Average
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Life (Years)	3 years 6 months	3 years 8 months 12 days

Intangible Assets, Net and Ce_4

Intangible Assets, Net and Certain Cloud Computing Costs - Amortization by Components (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 95,057	$ 66,860
Amortization of capitalized software development costs	30,876	16,601
Intangible Assets, Acquired
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 64,181	$ 50,259

Intangible Assets, Net and Ce_5

Intangible Assets, Net and Certain Cloud Computing Costs - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Change in Accounting Estimate [Line Items]
Amortization of intangible assets	$ 95,057	$ 66,860
Earnings per share, basic (in dollars per share)	$ (0.49)	$ (0.42)
Earnings per share, diluted (in dollars per share)	$ (0.49)	$ (0.42)
Net cloud computing costs	$ 42,000		$ 41,100
Cloud computing expense	1,200	$ 800
Change in Accounting Method Accounted for as Change in Estimate
Change in Accounting Estimate [Line Items]
Amortization of intangible assets	$ 18,600
Earnings per share, basic (in dollars per share)	$ 0.11
Earnings per share, diluted (in dollars per share)	$ 0.11

Intangible Assets, Net and Ce_6

Intangible Assets, Net and Certain Cloud Computing Costs - Periodic Amortization of Intangible Assets to be Charged to Expense over the Remaining Life of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 272,784
2025	280,727
2026	223,039
2027	163,836
2028 and thereafter	673,852
Net Carrying Value	$ 1,614,238	$ 1,677,781

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Total	Total
Client performance guarantees and accrued rebates	$ 36,282	$ 36,934
Marketing and advertising	38,724	34,427
Consulting fees/provider fees	16,443	16,416
Franchise, sales and other taxes	12,931	12,933
Operating lease liabilities – current	10,744	10,752
Professional fees	10,137	9,910
Information technology	7,968	7,605
Insurance	6,530	5,777
Interest payable	5,812	1,481
Income tax payable	4,127	621
Staff augmentation	3,532	4,287
Lease abandonment obligation - current	3,489	3,800
Other	42,699	33,691
Total	$ 199,418	$ 178,634

Convertible Senior Notes - Narr

Convertible Senior Notes - Narrative (Details) $ / shares in Units, shares in Millions			3 Months Ended
	May 19, 2020 USD ($)	May 08, 2018 USD ($)	Mar. 31, 2024 USD ($) day debtSeries $ / shares shares	Dec. 31, 2023 USD ($)	Jun. 04, 2020 USD ($)
Debt Instrument [Line Items]
Number of series of convertible senior debt outstanding | debtSeries			3
2027 Notes
Debt Instrument [Line Items]
Aggregate principal amount | $	$ 1,000,000,000		$ 1,000,000,000	$ 1,000,000,000
Interest rate	1.25%
Net proceeds from issuance of debt | $	$ 975,900,000
Offering costs | $	$ 24,100,000
2025 Notes
Debt Instrument [Line Items]
Aggregate principal amount | $		$ 287,500,000	725,000	725,000
Interest rate		1.375%
Net proceeds from issuance of debt | $		$ 279,100,000
Offering costs | $		$ 8,400,000
Livongo Notes
Debt Instrument [Line Items]
Aggregate principal amount | $			$ 550,000,000	$ 550,000,000	$ 550,000,000
Interest rate					0.875%
Convertible debt, threshold, trading days preceding maturity date (in days) | day			41
Convertible debt, consecutive trading days, measurement period (in days) | day			5
Convertible debt, reference property rate			0.592
Convertible debt, Reference property , conversion price (in dollars per share) | $ / shares			$ 4.24
Trading day observation period (in days) | day			40
Percentage of principal for repurchase price			100%
Convertible Notes Payable
Debt Instrument [Line Items]
Principal multiple amount used in the conversion of the debt instrument | $			$ 1,000
Convertible debt, threshold, trading days (in days) | day			20
Convertible debt, threshold, consecutive trading days (in days) | day			30
Minimum percentage of common stock price as a percentage of the conversion price			130%
Convertible debt, business days, measurement period (in days) | day			5
Convertible debt, consecutive trading days, measurement period (in days) | day			10
Trading price threshold			98%
Shares reserved for issuance (in shares) | shares			8.7
2027 Notes, 2025 Notes and the 2022 Notes
Debt Instrument [Line Items]
Trading day observation period (in days) | day			25

Convertible Senior Notes - Debt

Convertible Senior Notes - Debt Outstanding (Details)	3 Months Ended
	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
2027 Notes
Debt Instrument [Line Items]
Principal Amount Outstanding	$ 1,000,000,000
Interest Rate Per Year	1.25%
Fair value	$ 843,000,000	$ 822,000,000
Conversion ratio	0.0041258
Remaining Contractual Life	3 years 2 months 12 days
2025 Notes
Debt Instrument [Line Items]
Principal Amount Outstanding	$ 700,000
Interest Rate Per Year	1.375%
Fair value	$ 200,000	300,000
Conversion ratio	0.0186621
Remaining Contractual Life	1 year 1 month 6 days
Livongo Notes
Debt Instrument [Line Items]
Principal Amount Outstanding	$ 550,000,000
Interest Rate Per Year	0.875%
Fair value	$ 519,800,000	$ 513,700,000
Conversion ratio	0.01394
Remaining Contractual Life	1 year 2 months 12 days
Convertible Notes Payable
Debt Instrument [Line Items]
Principal multiple amount used in the conversion of the debt instrument	$ 1,000

Convertible Senior Notes - Net

Convertible Senior Notes - Net Carrying Values of Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Jun. 04, 2020	May 19, 2020	May 08, 2018
Debt Instrument [Line Items]
Net carrying amount	$ 1,539,546	$ 1,538,688
2027 Notes
Debt Instrument [Line Items]
Principal	1,000,000	1,000,000		$ 1,000,000
Less: Debt discount, net	(11,175)	(12,033)
Net carrying amount	988,825	987,967
2025 Notes
Debt Instrument [Line Items]
Principal	725	725			$ 287,500
Less: Debt discount, net	(4)	(4)
Net carrying amount	721	721
Livongo Notes
Debt Instrument [Line Items]
Principal	550,000	550,000	$ 550,000
Less: Debt discount, net	0	0
Net carrying amount	$ 550,000	$ 550,000

Convertible Senior Notes - Tota

Convertible Senior Notes - Total Interest Expense Recognized Related to Debt (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
2027 Notes
Debt Instrument [Line Items]
Contractual interest expense	$ 3,125	$ 3,125
Amortization of debt discount	858	844
Total	$ 3,983	$ 3,969
Effective interest rate	1.60%	1.60%
2025 Notes
Debt Instrument [Line Items]
Contractual interest expense	$ 2	$ 2
Amortization of debt discount	1	1
Total	$ 3	$ 3
Effective interest rate	1.80%	1.60%
Livongo Notes
Debt Instrument [Line Items]
Contractual interest expense	$ 1,203	$ 1,203
Amortization of debt discount	0	0
Total	$ 1,203	$ 1,203
Effective interest rate	0.90%	1.30%

Leases - Narrative (Details)

Leases - Narrative (Details)	Mar. 31, 2024
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease terms	1 year
Options to extend lease terms	1 year
Lessor lease term	2 years
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease terms	9 years
Options to extend lease terms	5 years
Lessor lease term	5 years

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Operating Leases:
2024	$ 9,979
2025	12,260
2026	11,101
2027	8,088
2028	5,918
2029 and thereafter	12,985
Total future minimum payments	60,331
Less: imputed interest	(9,616)
Present value of lease liabilities	50,715
Accrued expenses and other current liabilities	$ 10,744	$ 10,752
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued expenses and other current liabilities	Accrued expenses and other current liabilities
Operating lease liabilities, net of current portion	$ 39,971	$ 42,837

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 9,673	$ 8,102
Severance
Restructuring Cost and Reserve [Line Items]
Restructuring costs	7,000	7,200
Other Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring costs	2,700
Lease Termination
Restructuring Cost and Reserve [Line Items]
Restructuring costs		$ 900
Minimum
Restructuring Cost and Reserve [Line Items]
Expected pre-tax charges for restructuring	12,000
Maximum
Restructuring Cost and Reserve [Line Items]
Expected pre-tax charges for restructuring	$ 16,000

Restructuring - Accrual and Cha

Restructuring - Accrual and Charges Incurred Related to Restructuring (Details) - Restructuring Plan $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Restructuring Reserve [Roll Forward]
Balance at beginning of year	$ 3,800
Additional expenses (recoveries)	9,673
Cash payments	(8,019)
Balance at end of year	5,454
Severance
Restructuring Reserve [Roll Forward]
Balance at beginning of year	0
Additional expenses (recoveries)	6,957
Cash payments	(6,769)
Balance at end of year	188
Lease Termination
Restructuring Reserve [Roll Forward]
Balance at beginning of year	3,800
Additional expenses (recoveries)	(14)
Cash payments	(297)
Balance at end of year	3,489
Other
Restructuring Reserve [Roll Forward]
Balance at beginning of year	0
Additional expenses (recoveries)	2,730
Cash payments	(953)
Balance at end of year	$ 1,777

Common Stock and Stockholders_3

Common Stock and Stockholders' Equity - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares available for grant (in shares)	8,768,512
Grant-date fair value of stock options granted	$ 400	$ 200
Stock-based compensation expense	$ 42,325	$ 46,038
Stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	4 years
Dividend yield	0%	0%
Stock-based compensation expense	$ 1,700	$ 2,200
Unrecognized compensation cost for stock options	$ 11,200
Period over which unrecognized compensation cost is expected to be recognized	2 years
Stock options | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercisable period (in years)	10 years
Restricted Stock Units (RSUs)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years
Stock-based compensation expense	$ 37,300	38,800
Period over which unrecognized compensation cost is expected to be recognized	2 years
Grant-date fair value of restricted stock options granted	$ 67,100	169,100
Unrecognized compensation cost related to non vested awards	$ 246,800
Restricted Stock Units (RSUs) | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	1 year
Restricted Stock Units (RSUs) | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years
Performance Shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	$ 2,600	3,400
Period over which unrecognized compensation cost is expected to be recognized	2 years 2 months 12 days
Grant-date fair value of restricted stock options granted	$ 20,400	30,300
Unrecognized compensation cost related to non vested awards	$ 30,700
Performance Shares | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	1 year
Actual performance compared to performance conditions percentage	0%
Performance Shares | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years
Actual performance compared to performance conditions percentage	200%
ESPP
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	$ 800	$ 1,600
Period over which unrecognized compensation cost is expected to be recognized	1 month 6 days
Additional shares reserved for issuance under the plan (in shares)	3,000,000
Shares reserved for issuance under the plan (in shares)	4,113,343
Maximum offering period	27 months
Stock purchase price as a percentage of fair value	85%
Issuance of stock under employee stock purchase plan (in shares)	0	0
Remaining shares available for issuance under the plan (in shares)	2,800,781
Unrecognized compensation cost	$ 300

Common Stock and Stockholders_4

Common Stock and Stockholders' Equity - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Number of Shares Outstanding
Balance at beginning of period (in shares)	4,182,187
Stock option grants (in shares)	32,477
Stock options exercised (in shares)	(24,072)
Stock options forfeited (in shares)	(148,705)
Balance at end of period (in shares)	4,041,887	4,182,187
Vested or expected to vest at end of period (in shares)	4,041,887
Exercisable at end of period (in shares)	3,274,003
Weighted- Average Exercise Price
Balance at beginning of period (in dollars per share)	$ 27.37
Stock option grants (in dollars per share)	20.66
Stock options exercised (in dollars per share)	5.45
Stock options forfeited (in dollars per share)	39.78
Balance at end of period (in dollars per share)	27.13	$ 27.37
Weighted-average exercise price, vested or expected to vest at end of period (in dollars per share)	27.13
Weighted-average exercise price, exercisable at end of period (in dollars per share)	$ 26.43
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Weighted-average remaining contractual life in years	4 years 9 months	5 years 3 months 3 days
Weighted-average remaining contractual life in years, vested or expected to vest at end of period	4 years 9 months
Weighted-average remaining contractual life in years, exercisable at end of period	3 years 9 months 29 days
Aggregate intrinsic value	$ 5,669	$ 13,732
Aggregate intrinsic value, stock options exercised	291
Aggregate intrinsic value, vested or expected to vest at end of period	5,669
Aggregate intrinsic value, exercisable at end of period	$ 5,669

Common Stock and Stockholders_5

Common Stock and Stockholders' Equity - Assumptions Used for Estimate of Fair Value of Options (Details) - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Volatility, minimum	67.86%
Volatility, maximum	67.94%
Volatility		65.58%
Risk-free interest rate, minimum	3.85%
Risk-free interest rate, maximum	3.90%
Risk-free interest rate		4.07%
Stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (in years)	4 years 3 months 18 days	4 years 3 months 18 days
Dividend yield	0%	0%
Weighted-average fair value of the underlying stock options (in dollars per share)	$ 11.55	$ 12.85

Common Stock and Stockholders_6

Common Stock and Stockholders' Equity - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs)	3 Months Ended
	Mar. 31, 2024 $ / shares shares
RSUs
Balance at beginning of period (in shares) | shares	9,452,412
Granted (in shares) | shares	4,447,425
Vested and issued (in shares) | shares	(2,451,940)
Forfeited (in shares) | shares	(571,190)
Balance at end of period (in shares) | shares	10,876,707
Vested and unissued at end of period (in shares) | shares	43,118
Non-vested at end of period (in shares) | shares	10,833,589
Weighted-Average Grant Date Fair Value Per RSU
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 34.70
Granted (in dollars per share) | $ / shares	15.09
Vested and issued (in dollars per share) | $ / shares	39.04
Forfeited (in dollars per share) | $ / shares	33.54
Outstanding at end of period (in dollars per share) | $ / shares	25.82
Weighted-average grant date, fair value vested and unissued at end of period (in dollars per share) | $ / shares	56.25
Weighted-average grant date, fair value , non-vested at end of period (in dollars per share) | $ / shares	$ 25.70

Common Stock and Stockholders_7

Common Stock and Stockholders' Equity - Performance-Based Units Activity (Details) - Performance Shares	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Shares
Balance at beginning of period (in shares) | shares	1,452,387
Granted (in shares) | shares	1,359,651
Vested and issued (in shares) | shares	(179,764)
Forfeited (in shares) | shares	(23,240)
Performance adjustment (in shares) | shares	(241,073)
Balance at end of period (in shares) | shares	2,367,961
Vested and unissued at end of period (in shares) | shares	0
Non-vested at end of period (in shares) | shares	2,367,961
Weighted-Average Grant Date Fair Value Per PSU
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 36.82
Granted (in dollars per share) | $ / shares	15.03
Vested and issued (in dollars per share) | $ / shares	56.25
Forfeited (in dollars per share) | $ / shares	26.88
Performance adjustment (in dollars per share) | $ / shares
Outstanding at end of period (in dollars per share) | $ / shares	22.73
Weighted-average grant date, fair value vested and unissued at end of period (in dollars per share) | $ / shares	0
Weighted-average grant date, fair value , non-vested at end of period (in dollars per share) | $ / shares	$ 22.73
Minimum
Weighted-Average Grant Date Fair Value Per PSU
Percentage of target award	0%
Maximum
Weighted-Average Grant Date Fair Value Per PSU
Percentage of target award	85.20%

Common Stock and Stockholders_8

Common Stock and Stockholders' Equity - Total Compensation Costs for Stock-Based Awards (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 42,325	$ 46,038
Capitalized stock-based compensation	3,897	4,596
Total stock-based compensation	46,222	50,634
Cost of revenue (exclusive of depreciation and amortization, which are shown separately)
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	1,394	1,353
Advertising and marketing
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	3,789	3,126
Sales
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	7,967	8,075
Technology and development
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	9,299	12,729
General and administrative
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 19,876	$ 20,755

Provision for Income Taxes (Det

Provision for Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income tax expense	$ 2,690	$ 681

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Jul. 14, 2023 USD ($)
Federal Trade Commission
Loss Contingencies [Line Items]
Litigation settlement, amount awarded to other party	$ 7.8

Segments - Narrative (Details)

Segments - Narrative (Details)	3 Months Ended
	Mar. 31, 2024 segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segments - Revenues by Segment

Segments - Revenues by Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Information [Line Items]
Total Consolidated Revenue	$ 646,131	$ 629,244
Operating Segments | Teladoc Health Integrated Care
Segment Reporting Information [Line Items]
Total Consolidated Revenue	377,111	349,972
Operating Segments | BetterHelp
Segment Reporting Information [Line Items]
Total Consolidated Revenue	$ 269,020	$ 279,272

Segments - Adjusted EBITDA by S

Segments - Adjusted EBITDA by Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Information [Line Items]
Total Consolidated Adjusted EBITDA	$ 63,140	$ 52,765
Operating Segments | Teladoc Health Integrated Care
Segment Reporting Information [Line Items]
Total Consolidated Adjusted EBITDA	47,674	35,127
Operating Segments | BetterHelp
Segment Reporting Information [Line Items]
Total Consolidated Adjusted EBITDA	$ 15,466	$ 17,638

Segments - Reconciliation of Se

Segments - Reconciliation of Segment Profitability Adjusted EBITDA to Consolidated Net Loss (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Information [Line Items]
Total Consolidated Adjusted EBITDA	$ 63,140	$ 52,765
Less adjustments to reconcile to GAAP net loss
Interest income	(13,942)	(8,911)
Interest expense	5,649	5,263
Other expense (income), net	370	(4,907)
Amortization of intangible assets	95,057	66,860
Depreciation of property and equipment	2,834	2,923
Stock-based compensation expense	42,325	46,038
Acquisition, integration, and transformation costs	373	5,944
Restructuring costs	9,673	8,102
Loss before provision for income taxes	(79,199)	(68,547)
Provision for income taxes	2,690	681
Net loss	(81,889)	(69,228)
Operating Segments | Teladoc Health Integrated Care
Segment Reporting Information [Line Items]
Total Consolidated Adjusted EBITDA	47,674	35,127
Operating Segments | BetterHelp
Segment Reporting Information [Line Items]
Total Consolidated Adjusted EBITDA	$ 15,466	$ 17,638

Segments - Geographic Data for

Segments - Geographic Data for Long-Lived Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	$ 29,550	$ 32,032
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	26,519	28,096
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	$ 3,031	$ 3,936

Subsequent Event (Details)

Subsequent Event (Details) - Forecast $ in Millions	Jun. 30, 2024 USD ($)
Separation
Subsequent Event [Line Items]
Expected costs for restructuring	$ 6.4
Salary Continuation and 2024 Pro-rated Annual Bonus
Subsequent Event [Line Items]
Expected costs for restructuring	1.2
Stock-based Compensation
Subsequent Event [Line Items]
Expected costs for restructuring	$ 5.2